Cohance Lifesciences Stock Screener | Share Price & Fundamental Analysis
COHANCE
Pharmaceuticals
Screen Cohance Lifesciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹513.20
▼
-5.10 (-0.98%)
Share Price BSE
₹512.90
▼
-4.25 (-0.82%)
Market Cap
₹20,235.89 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.34
EPS (TTM)
₹10.52
Dividend Yield
-
Debt to Equity
0.09
52W High
₹1230.00
52W Low
₹513.20
Operating Margin
25.00%
Profit Margin
13.72%
Revenue (TTM)
₹853.00
EBITDA
₹226.00
Net Income
₹117.00
Total Assets
₹3,032.00
Total Equity
₹1,841.00
Cohance Lifesciences Share Price History - Stock Screener Chart
Screen COHANCE historical share price movements with interactive charts. Analyze price trends and patterns.
Cohance Lifesciences Company Profile - Fundamental Screener
Screen Cohance Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for COHANCE shares.
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Vivek Sharma
ISIN
INE03QK01018
Website
https://www.suvenpharm.com
Cohance Lifesciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen COHANCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 3,032 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Assets | 889 | 1,263 | 1,011 | 1,128 | 565 | 392 | 390 |
| Fixed Assets | 1,713 | 670 | 663 | 534 | 441 | 357 | 271 |
| Liabilities | |||||||
| Total Liabilities | 3,032 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Liabilities | 826 | 97 | 72 | 92 | 74 | 128 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 1,841 | 2,051 | 1,735 | 1,527 | 1,181 | 845 | 590 |
| Share Capital | 26 | 26 | 26 | 26 | 26 | 13 | 13 |
| Reserves & Surplus | 1,671 | 2,025 | 1,710 | 1,502 | 1,155 | 832 | 578 |
Screen COHANCE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 853 | 564 | 571 | 270 | 508 | 620 | 323 | 381 | 358 | 251 | 234 | 381 | 350 | 289 | 367 |
| Expenses | 627 | 445 | 435 | 180 | 363 | 398 | 189 | 198 | 181 | 133 | 154 | 207 | 188 | 179 | 207 |
| EBITDA | 226 | 118 | 137 | 90 | 145 | 222 | 133 | 183 | 178 | 118 | 80 | 174 | 162 | 111 | 160 |
| Operating Profit % | 25.00% | 19.00% | 22.00% | 29.00% | 26.00% | 34.00% | 38.00% | 47.00% | 48.00% | 42.00% | 30.00% | 43.00% | 45.00% | 36.00% | 41.00% |
| Depreciation | 54 | 45 | 44 | 17 | 31 | 38 | 20 | 12 | 13 | 12 | 13 | 10 | 12 | 12 | 12 |
| Interest | 10 | 10 | 9 | 2 | 10 | 10 | 3 | 5 | 1 | 1 | 2 | 2 | 2 | 0 | 1 |
| Profit Before Tax | 161 | 63 | 84 | 71 | 103 | 174 | 110 | 166 | 164 | 105 | 66 | 161 | 149 | 99 | 146 |
| Tax | 44 | 16 | 17 | 18 | 28 | 36 | 26 | 42 | 43 | 26 | 19 | 70 | 41 | 26 | 38 |
| Net Profit | 117 | 46 | 66 | 53 | 75 | 138 | 83 | 124 | 121 | 80 | 47 | 92 | 108 | 72 | 108 |
| EPS | 3.16 | 1.28 | 1.94 | 2.10 | 1.98 | 3.63 | 3.26 | 4.87 | 4.74 | 3.13 | 1.84 | 3.60 | 4.22 | 2.83 | 4.23 |
Cohance Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen COHANCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 288 | 359 | 457 | 330 | 383 | 407 | 50 |
| Investing Activities | -253 | -362 | -195 | -136 | -311 | -414 | -66 |
| Financing Activities | 3 | -14 | -242 | -156 | -76 | 7 | 26 |
| Net Cash Flow | 38 | -18 | 20 | 37 | -5 | 1 | 11 |
Screen COHANCE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-May | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.10% | 66.41% | 66.41% | 57.49% | 50.10% | 50.10% | 50.10% | 50.10% |
| FII Holding | 11.05% | 7.38% | 7.23% | 6.51% | 9.54% | 9.80% | 10.70% | 10.84% |
| DII Holding | 16.60% | 11.02% | 11.40% | 20.82% | 17.24% | 17.42% | 16.94% | 16.68% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 9.68% | 6.63% | 6.40% | 6.42% | 10.51% | 10.08% | 9.75% | 9.81% |
| Other Holding | 12.55% | 8.55% | 8.55% | 8.75% | 12.59% | 12.59% | 12.50% | 12.56% |
| Shareholder Count | 86,325 | 88,658 | 80,910 | 75,284 | 68,932 | 65,777 | 69,337 | 84,210 |
Cohance Lifesciences Dividend Screener - Share Yield Analysis
Screen COHANCE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹6.00 | 0.89% |
| 2022-March | ₹5.00 | 1.06% |
| 2021-March | ₹2.00 | 0.32% |
| 2020-March | ₹5.00 | 1.01% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Cohance Lifesciences Index Membership - Market Screener Classification
Screen COHANCE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Cohance Lifesciences Market Events Screener - Corporate Actions
Screen COHANCE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 5.00 /share | -3.05% | ||
| Bonus | 1:1 | 0.04% | ||
| Annual General Meeting | NA | -6.87% | ||
| Dividend | ₹ 1.00 /share | -3.05% | ||
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -1.67% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -20.48% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -5.19% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -5.13% |
| 2025-05-07 | 2025-05-07 | Change Of Name | NA | 0.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.54% |
| 2024-11-28 | 2024-11-28 | Extraordinary General Meeting | NA | -0.62% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 4.44% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 16.74% |
| 2023-12-15 | 2023-12-15 | Annual General Meeting | NA | 17.68% |
| 2022-05-13 | 2022-05-17 | Dividend | ₹ 1.00 /share | -12.53% |
Cohance Lifesciences Competitors Screener - Peer Comparison
Screen COHANCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,686 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 169,847 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,186 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 122,135 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 105,998 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,567 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,553 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 90,900 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 69,115 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,486 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Cohance Lifesciences Company Announcements - News Screener
Screen COHANCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Closure of Trading Window | View |
| 2026-01-03 | Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine-Months Ending December 31 2025 | View |
| 2026-01-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-28 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-12-13 | Intimation Of Change In Website Address Of The Company | View |
| 2025-12-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-03 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-12-03 | Grant Of Stock Options | View |
| 2025-12-02 | General Updates | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-12 | Outcome Of The Meeting | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of The Board Meeting | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |